Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms

Synapse

Volumn 29, Issue 1, 1998, Pages 37-61

  Cumming, Paul ^a   Gjedde, Albert ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Catechol O methyltransferase; Compartmental modelling; Dopa; Dopa decarboxylase; Fluorodopa; Kinetics; Parkinson's disease; Positron emission tomography

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE;

AGING; ARTICLE; BRAIN SCINTISCANNING; BRAIN SIZE; DECARBOXYLATION; DIAGNOSTIC VALUE; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; ENZYME ACTIVITY; HUMAN; ISOTOPE LABELING; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; CATECHOL O-METHYLTRANSFERASE; DECARBOXYLATION; DIHYDROXYPHENYLALANINE; DOPA DECARBOXYLASE; HUMANS; MODELS, NEUROLOGICAL; NERVOUS SYSTEM DISEASES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031979045     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199805)29:1<37::AID-SYN4>3.0.CO;2-C     Document Type: Article

References (189)

1. 11C]5-hydroxytryptophan in major depression: A positron emission tomography study on patients and healthy volunteers. Acta Psychiatr. Scand., 83:449-455.
2. Antonini, A., Vontobel, P., Psylla, M., Günther, I., Maguire, P.R., Missimer, J., and Leenders, K.L. (1995) Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol., 52:1183-1190.
3. Bäckström, R., Honkanen, E., Pippuri, A., Kairisalo, P., Pystynen, J., Heinola, K., Nissinen, E., Lindén, I.-B., Männistö, P.T., Kaakkola, S., and Pohto, P. (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J. Med. Chem., 32:841-846.
4. Baker, G.B., Nazarali, A.J., Coutts, R.T., Micetich, R.G., and Hall, T.W. (1984) Brain levels of 5-hydroxytryptamine, tryptamine and 2-phenylethylamine in the rat after administration of N-cyanoethyltranylcypromine. Prog. Neuropsychopharmacol. Biol. Psychiatry, 8:657-660.
5. Barrio, J.R., Huang, S.C., and Phelps, M.E. (1997) Biological imaging and the molecular basis of dopaminergic diseases. Biochem. Pharmacol. 54:341-348.
6. 18F]Fluoro-L-DOPA probes dopamine turnover rates in centra] dopaminergic structures. J. Neurosci. Res., 27:487-493.
7. Barrio, J.R., Huang, S.-C., Yu, D.-C., Melega, W.P., Quintana, J., Cherry, S.R., Jacobson, A., Namavari, M., Satyamurthy, N., and Phelps, M.E. (1996) Radiofluorinated L-m-tyrosines: New in-vivo probes for central dopamine biochemistry. J. Cereb. Blood Flow Metab., 16:667-678.
8. Bhatt, M.H., Snow, B.J., Martin, W.R.W., Cooper, S., and Calne, D.B. (1990) Positron emission tomography in Shy-Drager syndrome. Ann. Neurol., 28:101-103.
9. Bouchard, S., and Roberge, A.G. (1979) Biochemical properties and kinetic parameters of dihydroxyphenylalanine-5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. Can. J. Biochem., 57:1014-1018.
10. 18F]-6-fluorodopa during positron emission tomography: Elimination and metabolism in carbidopa treated subjects. Life Sci., 39:2243-2252.
11. Brøndsted, H.E., and Gjedde, A. (1988) Measuring brain glucose phosphorylation with labelled glucose. Am. J. Physiol., 254:E443-448.
12. Brooks, D.J., Salmon, E.P., Mathias, C.J., Quinn, N., Leenders, K.L., Bannister, R., Marsden, C.D., and Frackowiak, R.S.J. (1990a) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multisystem atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain, 113:1539-1552.
13. Brooks, D.J., Ibanez, V., Sawle, G.V., Quinn, N., Lees, A.J., Mathias, C.J., Bannister, R., Marsden, C.D., and Frackowiak, R.S.J. (1990b) Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol., 28:547-555.
14. Brooks, D.J., Ibanez, V., Playford, E.D., Sawle, G.V., Leigh, P.N., Kocen, R.S., Harding, A.E., and Marsden, C.D. (1991) Presynaptic and postsynaptic striatal dopmainergic function in neuroacanthocytosis: A positron emission tomographic study. Ann. Neurol., 30:166-171.
15. Brust, P., Bauer, R., Walter, B., Bergmann, R., Vorwieger, G., Füchtner, F., Steinbach, J., Will, E., Linemann, H., Zwiener, U., and Johannsen, B. (1997) Effect of asphyxia on the activity of the aromatic L-amino acid decarboxylase (AADC) in the brain of neonatal pigs. Brain 97, 18th Symposium on Cerebral Blood Flow, Baltimore, June 15-19.
16. Buckland, P.R., O'Donovan, M.C., and McGuffin, P. (1992) Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA in rat brain following antipsychotic treatment. Psychopharmacology, 108:98-102.
17. Buckland, P.R., Spurlock, G., and McGuffin, P. (1996) Amphetamine and vigabatrin regulate aromatic L-amino acid decarboxylase mRNA levels. Mol. Brain Res., 35:69-76.
18. 18F]6-fluorodopa input function: A simplified method. J. Cereb. Blood Flow Metab., 12:881-884.
19. 18F]fluoro-L-DOPA/PET scans in non-human primates. Life Sci., 56:1759-1766.
20. 3H]mazindol. Neuroscience, 49:317-327.
21. Cho, S., Duchemin, A.-M., Neff, N.H., and Hadjiconstantinou, M. (1996) Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibition of monoamine oxidase-A. Eur. J. Pharmacol., 314:51-59.
22. Christenson, J.G., Dairman, W., and Udenfriend, S. (1970) Preparation and properties of a homogeneous aromatic L-amino acid decarboxylase from hog kidney. Arch. Biochem. Biophys., 141:356-367.
23. 18F]fluoro-L-dopa positron emission tomography in progressive supranuclear palsy. Neuroradiology, 35:404-409.
24. Cordes, M., Snow, B.J., Cooper, S., Schulzer, M., Pate, B.D., Ruth, T.J., and Calne, D.B. (1994) Age-dependent decline of nigrostriatal dopaminergic function: A positron emission tomographic study of grandparents and their grandchildren. Ann. Neurol., 36:667-670.
25. Cumming, P., Reith, J., and Gjedde, A. (1997d) Recent papers on FDOPA suffer from major shortcomings [Letter]. J. Nucl. Medicine, 38:1267-1269.
26. 18F]-6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat. J. Neurochem., 48:601-608.
27. 18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. Biochem. Pharmacol., 36:2527-2531.
28. 18F]-fluorodopa in the hooded rat. Biochem. Pharmacol., 37:247-250.
29. Cumming, P., Brown, E., Damsma, G., and Fibiger, H.C. (1992) Formation and clearance of interstitial metabolites of dopamine and serotonin in rat striatum: An in vivo microdialysis study. J. Neurochem., 59:1905-1914.
30. 18F]FDOPA) in humans. J. Cereb. Blood Flow Metab., 13:668-675.
31. 14C]-α-methyl-para-tyrosine. Synapse, 17:125-128.
32. 18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. J. Neurochem., 63:1675-1682.
33. Cumming, P., Kuwabara, H., Ase, A., and Gjedde, A. (1995a) Regulation of DOPA decarboxylase activity in brain of living rat. J. Neurochem., 65:1381-1390.
34. 18F]FDOPA) in the rat. Biochem. Pharmacol., 50:943-946.
35. Cumming, P., Deep, P., and Gjedde, A. (1997a) On the rate of decarboxylation of dopa to dopamine in living mammalian brain. In: Frontiers of Neurology. Annals of the New York Academy of Sciences. D.J. Reis and J. Posner, eds. NYAS Press, New York.
36. 3H]DOPA in the telencephalon of the living rat. Brain Res., 747:60-69.
37. 3H]tyrosine in brain of living rat is not committed to dopamine synthesis. J. Cereb. Blood Flow Metab. (in press).
38. Cumming, P., Ase, A., Laliberté, C., Kuwabara, H., and Gjedde, A. (1997c) In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J. Cereb. Blood Flow Metab. 17:1254-1260.
39. Dairman, W., Christenson, J.G., and Udenfriend, S. (1972) Changes in tyrosine hydroxylase and dopa decarboxylase induced by pharmacological agents. Pharmacol. Rev., 24:269-289.
40. 18F]-DOPA in pigs estimated by PET [Abstract]. BrainPET 97, Washington, D.C.
41. Dedek, J., Baumes, R., Tien-Duc, N., Gomeni, R., and Korf, J. (1979) Turnover of free and conjugated (sulfonyloxyl)-dihydroxyphenylacetic acid and homovanillic acid in rat striatum. J. Neurochem., 33:687-695.
42. 3H]DOPA in rat investigated by compartmental modelling of autoradiograms. J. Neurosci. Methods (in press).
43. 18F]fluorodopamine. J. Neurosci. Methods 76:157-165.
44. DeJesus, O.T., and Mukherjee, J. (1988) Radiobrominated m-tyrosine as potential CNS L-DOPA PET tracer. Biochem. Biophys. Res. Comm., 150:1027-1031.
45. 18F]fluoro-β-fluoromethylene-m-tyrosine. Brain Res., 597:151-154.
46. DeJesus, O.T., Endres, C.J., Shelton, S.E., Nickles, R.J., and Holden, J.E. (1997) Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: Comparison with 6-fluorodopa. J. Nucl. Med., 38:630-636.
47. Dhawan, V., Ishikawa, T., Patlak, C., Chaly, T., Robeson, W., Belakhlef, A., Margouleff, C., Mandel, F., and Eidelberg, D. (1996) Combined FDOPA and 30MFD PET studies in Parkinson's disease. J. Nucl. Med., 37:209-216.
48. 18F]fluoro-L-DOPA in the rhesus monkey brain. J. Cereb. Blood Flow Metab., 11:726-734.
49. Dyck, L.E. (1987) Effect of monofluoromethyldopa (MFMD) on trace amine levels. Life Sci., 40:571-575.
50. 18F-DOPA uptake: Absence of an aging effect. J. Cereb. Blood Flow Metab., 13:881-888.
51. Endres, C.J., Swaminathan, S., DeJesus, O.T., Sievert, M., Ruoho, A.E., Murali, D., Rommelfanger, S.G., and Holden, J.E. (1997) Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: Implication for PET dopamine studies. Life Sci., 60:2399-2406.
52. Ernst, M., Zametkin, A.J., Matochik, J.A., Pascualvaca, D., Jons, P.H., Hardy, K., Hankerson, J.G., Doudet, D.J., and Cohen, R.M. (1996) Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N. Engl. J. Med., 334:1568-1572.
53. 18F]Fluoro-dopa: A unique gamma emitting substrate for dopa decarboxylase. Experientia, 31:1254-1255.
54. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J. Neurochem., 48:1077-1082.
55. 18F]fluoro-L-DOPA in human blood. J. Nucl. Med., 29:363-369.
56. Freed, C.R., Breeze, R.E., Rosenberg, N.L., Schneck, S.A., Kriek, E., Qi, J.-X., Lone, T., Zhang, Y.-B., Snyder, J.A., Wells, T.H., Ramig, L.O., Thompson, L., Mazziota, J.C., Huang, S.C., Grafton, S.T., Brooks, D., Sawle, G., Schroter, G., and Ansari, A.A. (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Eng. J. Med., 327:1549-1555.
57. Freeman, T.B., Olanow, C.W., Hauser, R.A., Nauert, G.M., Smith, D.A., Borlongan, C.V., Sanberg, P.R., Holt, D.A., Kordower, J.H., Vingerhoets, F.J.G., Snow, B.J., Calne, D., and Gauger, L.L. (1995) Bilateral fetal nigral transplantation into the postcommisural putamen in Parkinson's disease. Ann. Neurol., 38:379-388.
58. Garnett, E.S., Firnau, G., Nahmias, C., Sood, S., and Belbeck, L. (1980) Blood-brain transport and cerebral utilization of dopa in living monkeys. Am. J. Physiol., 238:R318-327.
59. Garnett, E.S., Firnau, G., Nahmias, C., and Chirakal, R. (1983a) Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res., 280:169-171.
60. Garnett, E.S., Firnau, G., and Nahmias, C. (1983b) Dopamine visualized in the basal ganglia of living man. Nature, 305:137-138.
61. Garnett, E.S.D., Nahmias, C., and Firnau, G. (1984) Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can. J. Neurol. Sci., 11:174-179.
62. Gjedde, A. (1981) High- and low-affinity transport of D-glucose from blood to brain. J. Neurochem., 36:1463-1471.
63. Gjedde, A. (1982) Calculation of glucose phosphorylation from brain uptake of glucose analogues in vivo: A re-examination. Brain Res., 257:237-274.
64. Gjedde, A. (1988) Exchange diffusion of large neutral amino acids between blood and brain. In: Peptide and Amino Acid Transport Mechanisms in the Central Nervous System. Rakic, L., Begley, D.J., Davson, H., and Zlokovic, B.V., eds. London: MacMillan, 1988, pp. 209-217.
65. Gjedde, A., Reith, J., Dyve, S., Léger, G., Guttman, M., Diksic, M., Evans, A., and Kuwabara, H. (1991) Dopa decarboxylase activity of the living human brain. Proc. Natl. Acad. Sci. USA, 88:2721-2725.
66. Gjedde, A., Léger, G.G., Cumming, P., Yasuhara, Y., Evans, A.C., Guttman, M., and Kuwabara, H. (1993) Stiatal L-DOPAdecarboxylase activity in Parkinson's disease in vivo: Implications for the regulation of dopamine synthesis. J. Neurochem., 61:1538-1541.
67. 3H]DOPA in various regions of the brain. J. Neurochem., 13:655-669.
68. Goldstein, D.S., Udelsman, R., Eisenhoffer, G., Stull, R., Keiser, H.R., and Kopin, I.J. (1987) Neuronal source of plasma dihydroxyphenylalanine. J. Clin. Endocrinol. Metab., 64:856-861.
69. Guttman, M., Léger, G., Cedarbaum, J.M., Reches, A., Woodward, W., Evans, A., Diksic, M., and Gjedde, A. (1992) 3-O-Methyldopa administration does not alter fluorodopa transport into the brain. Ann. Neurol., 31:638-643.
70. Guttman, M., Léger, G., Reches, A., Evans, A., Kuwabara, H., Cedarbaum, J.M., and Gjedde, A. (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Move. Disord., 8:298-304.
71. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: Implications for symptomatic threshold. Neurology, 48:1578-1583.
72. Hadjiconstantinou, W., Wemlinger, T.A., Silvia, C., Hubble, J.P., and Neff, N.H. (1993) Aromatic L -amino acid decarboxylase of mouse striatum is modulated via dopamine receptors. J. Neurochem., 60:2175-2180.
73. Hadjiconstantinou, M., Rossetti, Z.L., Wemlinger, T.M., and Neff, N.H. (1995) Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity. Eur. J. Pharmacol., 289:97-101.
74. Hammerstad, J.P., Pate, B.D., Hewitt, K.A., Chan, G.L.-Y., Ruth, T.J., and Calne, D.B. (1993) The transport of L-6-fluorodopa and its metabolites from blood to cerebospinal fluid and brain. Ann. Neurol., 34:603-608.
75. 11 C]DOPA in humans studies by positron emission tomography. J. Neural Transm., 86:25-41.
76. 11C)-L-dopa following COMT inhibition: A study in vivo using positron emission tomography. J. Neural Transm., 87:15-22.
77. 11C-labelled L-tryptophan and 5-hydroxy-L-tryptophan in the rhesus monkey: A study using positron emission tomography. J. Neural Transm., 88:1-10.
78. Hartvig, P., Lindner, K.J., Bjürling, P., Längström, B., and Tedroff, J. (1995) Pyridoxine effect on synthesis rate of serotonin in the monkey brain measured with positron emission tomography. J. Neural Transm., 102:91-97.
79. Hietala, J., Syvälahti, E., Vuorio, K., Räkköläinen, V., Bergman, J., Haarparanta, M., Solin, O., Kuoppamäki, M., Kirvelä, O., Ruotsaleinen, U., and Salokangas, R. (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet, 346:1130-1131.
80. 18F]fluoro-L-DOPA kinetics in positron emission tomography. J. Nucl. Med., 33:1472-1477.
81. Holthoff-Detto, V.A., Kessler, J., Herholz, K., Bönner, H., Pietrzyk, U., Würker, M., Ghaemi, M., Wienhard, K., Wagner, R., and Heiss, W.-D. (1997) Functional effects of striatal dysfunction in Parkinson's disease. Arch. Neurol., 54:145-150.
82. Horne, M.K., Cheng, C.H., and Wooten, G.F. (1984) The cerebral metabolism of L-dihydroxyphenylalanine: An autoradiographic and biochemical study. Pharmacology, 28:12-26.
83. 18F]fluoro-L-DOPA metabolism in living human brain: A comparison of six analytical methods. J. Cereb. Blood Flow Metab., 13:57-69.
84. 18F]fluoro-DOPA in human positron emission tomographic studies. J. Cereb. Blood Flow Metab., 11:898-913.
85. Hume, S.P., Lammertsma, A.A., Myers, R., Rajeswaran, S., Bloomfield, P.M., Ashworth, S., Fricker, R.A., Torres, E.M., Watson, A.C., and Jones, T. (1996) The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J. Neurosci. Meth., 67:103-112.
86. Ichinose, H., Kojima, K., Togari, A., Kato, Y., Parvez, S., Parvez, H., and Nagatsu, T. (1985) Simple purification of aromatic L-amino acid decarboxylase from human pheochromocytoma using high performance liquid chromatography. Anal. Biochem., 150:408-414.
87. Ishikawa, T., Dhawan, V., Chaly, T., Margouleff, C., Robeson, W., Dahl, J.R., Mandel, F., Spetsieris, P., and Eidelberg, D. (1996a) Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. J. Nucl. Med., 37:216-222.
88. Ishikawa, T., Dhawan, V., Chaly, T., Robeson, W., Belakhlef, A., Mandel, F., Dahl, R., Margouleff, C., and Eidelberg, D. (1996b) Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa on data analysis. J. Cereb. Blood Flow Metab., 16:854-863.
89. Ishikawa, T., Dhawan, V., Kazumata, K., Chaly, T., Mandel, F., Neumeyer, J., Margouleff, C., Babchyck, B., Zanzi, I., and Eidelberg, D. (1996c) Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET. J. Nucl. Med., 37:1760-1765.
90. 18F]-fluorophenylalanine and PET. J. Nucl. Med., 35:1232-1237.
91. Iversen, L.L., and Glowinski, J. (1966) Regional studies of catecholamines in the rat brain. II. Rate of turnover of catecholamines in various brain regions. J. Neurochem., 13:671-682.
92. Kish, S.J., Shannak, K., and Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications. N. Eng. J. Med., 318:876-880.
93. Kish, S.J., Shannak, K., Rajput, A., Deck, J.H.N., and Hornykiewicz, O. (1992) Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson's disease. J. Neurochem., 58:642-648.
94. Kish, S.J., Zhong, X.H., Hornykiewicz, O., and Haycock, J.W. (1995) Striatal 3,4-dihydroxyphenyalanie decarboxylase in aging: Disparity between postmortem and positron emission tomography studies? Ann. Neurol., 38:260-264.
95. Kishore, A., Wszolek, Z.K., Snow, B.J., de la Fuente-Fernandez, R., Arwert, F., Wijker, M., Schulzer, M., Calne, D.B., and Vingerhoets, F.J.G. (1996) Presynaptic nigrostriatal functino in genetically tested asymptomatic relative from the pallido-ponto-nigral degeneration family. Neurology, 47:1588-1590.
96. Korf, J., Reiffers, S., Beerling-van der Molen, H.D., Lakke, J.P.W.F., Paans, A.M.J., Vaalburg, W., and Woldring, M.G. (1978) Rapid decarboxylation of carbon-11 labelled DL-DOPA in the brain: A potential approach for external detection of nervous structures. Brain Res., 145:59-67.
97. 18F]fluoro-DOPA and positron emission tomography: Error analysis and application to normal subjects. J. Cereb. Blood Flow Metab., 13:43-56.
98. Kuwabara, H., Cumming, P., Léger, G., Guttman, M., Rajagopal, S., and Gjedde, A. (1993b) Dopamine turnover is increased in striatum of patients with Parkinson's disease. Brain 93, Sendai, Japan, May 22-28.
99. Kuwabara, H., Cumming, P., Yasuhara, Y., Léger, G.C., Guttman, M., Diksic, M., Evans, A.C., Gjedde, A. (1995) Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J. Nucl. Med., 36:1226-1231.
100. 18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology, 42:199-203.
101. 18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann. Neurol., 20:258-262.
102. Leenders, K.L., Palmer, A.J., Quinn, N., Clark, J.C., Firnau, G., Garnett, E.S., Nahmias, C., Jones, T., and Marsden, C.D. (1986b) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J. Neurol. Neurosurg. Psychiatry, 49:853-860.
103. 18F]fluorodopa using PET: Implications for compartmental modelling and clinical usefulness. Synapse (in press).
104. 3H]phenylalanine distribution in the rat. Neurosci. Lett., 53:161-167.
105. Lloyd, K., and Hornykiewicz, O. (1970) Parkinson's disease: Activity of L-DOPA edcarboxylase in discrete brain regions. Science, 170:1212-1213.
106. Lüdecke, B., Knappskog, P.M., Clayton, P.T., Surtees, R.A.H., Clelland, J.D., Heales, S.J.R., Brand, M.P., Bartholomé, K., and Flatmark, T. (1996) Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum. Mol. Genet., 5:1023-1028.
107. 18F]fluoro-L-DOPA and its metabolism in vivo - a critical review. Nucl. Med. Biol., 19:149-158.
108. Mackay, A.V.P., Davies, P., Dewar, A.J., and Yates, C.M. (1978) Regional distribution of enzymes associated with neurotransmission by monoamines, acetylcholine and GABA in human brain. J. Neurochem., 30:827-839.
109. Martin, W.R.W., Palmer, M.R., Patlak, C.S., and Calne, D.B. (1989) Nigrostriatal function in humans studies with positron emission tomography. Ann. Neurol., 26:535-542.
110. Meguro, K., Yamaguchi, S., Itoh, M., Fujiwara, T., and Yamadori, A. (1997) Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: A double tracer study. Neurology 49:941-945.
111. Melamed, E., Hefti, F., Pettibone, D.J., Liebman, J., and Wurtman, R.J. (1981) Aromatic L-amino acid decarboxylase in rat corpus striatum: Implications for action of L-dopa in parkinsonism. Neurology, 31:651-655.
112. 18F]Fluoro-L-m-tyrosine: An L-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography. J. Neurochem., 53:311-314.
113. 18F]fluoro-L-dopa in rats, monkeys and humans. Life Sci., 47:149-157.
114. 3H]L-DOPA in rats. Biochem. Pharmacol., 39:1853-1860.
115. 18F]Fluoro-DOPA metabolism in monkeys and humans: Biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J. Cereb. Blood Flow Metab., 11:890-897.
116. 18F]Fluoro-L-DOPA metabolism in MPTP-treated monkeys: Assessment of tracer methodologies for positron emission tomography. Brain Res., 543:271-276.
117. 18F]fluoro-L-DOPA/PET: Assessment in MPTP-hemiparkinsonan monkeys. Exp. Neurol., 141:318-329.
118. 18F]Fluoro-L-DOPA-PET studies show partial reversal of long-term effects of chronic amphetamine in monkeys. Synapse, 22:63-69.
119. Meltzer, C.C., Zubieta, J.K., Brand, F.J., Tune, L.E., Mayberg, H.S., and Frost, J.J. (1996) Regional hypometabolism in Alzheimer's disease as measured by PET after correction for effects of partial volume averaging. Neurology, 47:454-461.
120. 18F]Fluoro-L-dihydroxyphenylanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res., 626:1-13.
121. 11C]DOPA. Brain Res., 578:122-128.
122. 14C in the cat brain. Jpn. J. Pharmacol., 30:795-805.
123. 18F]dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 59:597-600.
124. 18F]DOPA PET study. In: Advances in Neurology, Volume 69. L. Battistin et al., eds. Lippincott-Raven, Philadelphia, pp. 427-431.
125. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain, 119:585-591.
126. 18F]dopa metabolism in the striatum in Parkinson's disease. Brain, 119:2097-2103.
127. Murphy, D.G.M., DeCarli, C., Schapiro, M.B., Rapoport, S.I., and Horwitz, B. (1992) Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men measured with magnetic resonance imaging. Arch. Neurol., 49:839-845.
128. 18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography. J Neurol Sci. 144:70-76.
129. Nagasawa, H., et al. (1996b). (The present Nagasawa reference becomes 1996b).
130. Nagasawa, H., Tanji, H., Nomura, H., Saito, H., Itoyama, Y., Kimura, I., Tuji, S., Fujiwara, T., Iwata, R., Itoh, M., and Ido, T. (1996) PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. J. Neurolog. Sci., 139:21-27.
131. 18F]6-fluoro-L-m-tyrosine in the human brain. Move. Disord., 10:298-304.
132. Nutt, J.G., Woodward, W.R., Beckner, R.M., Stone, C.K., Berggren, K., Carter, J.H., Gancher, S.T., Hammerstad, J.P., and Gordin, A. (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology, 44:913-919.
133. Okada, A., Nakamura, K., Snow, B.J., Bhatt, M.H., Nomoto, M., Osame, M., and Calne, D.B. (1993) PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). In: Advances in Neurology, Vol. 60. H. Narabayashi et al., eds. Raven Press, New York, pp. 591-594.
134. Opacka-Juffry, J., and Brooks, D.C. (1995) L-Dihydroxyphenlalanine and its decarboxylase: New ideas on their neuroregulatory roles. Move. Disord., 10:241-249.
135. Otsuka, M., Ichiya, Y., Kuwabara, Y., Hosokawa, S., Sasaki, M., Yoshida, T., Fukumura, T., Kato, M., and Masuda, K. (1996) Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study. J Neurol Sci. 144:77-83.
136. Palfreyman, M.G., McDonald, I.A., Fozard, J.R., Mely, Y., Sleight, A.J., Zreika, M., Wagner, J., Bey, P., and Lewis, P.J. (1985) Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-β-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase. J. Neurochem., 45:1850-1860.
137. Pate, B.D., Snow, B.J., Hewitt, K.A., Morrison, K.S., Ruth, T.J., and Calne, D.B. (1991) The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. J. Nucl. Med., 32:1246-1251.
138. Pate, B.D., Kawamata, T., Yamada, T., McGeer, E.G., Hewitt, K.A., Snow, B.J., Ruth, T.J., and Calne, D.B. (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol., 34:331-338.
139. Patlak, C.S., Blasberg, R.G., Fenstermacher, J.D. (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab., 3:1-7.
140. Patlak, C.S., Blasberg, R.G. (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab., 5:584-590.
141. 18F]fluoro-L-DOPA. Eur. J. Pharmacol., 257:53-58.
142. Phelps, M.E., Huang, S.C., Hoffman, E.J., Selin, C., Sokoloff, L., and Kohl, D.E. (1979) Tomographic measurement of local cerebral glucose metabolic
143. 18F-dopa positron emission tomography study. Ann. Neurol., 41:222-229.
144. Prasad, A.L.N., and Fahn, S. (1974) 3-O-methyl metabolites of catecholamines: Automated fluorometric assay and their plasma levels in patients receiving levodopa and carbidopa. Biochem. Med., 9:136-147.
145. 18F]fluoro-L-DOPA in rat. J. Cereb. Blood Flow Metab., 10:707-719.
146. Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., Dyve, S.E., Étienne, P., Evans, A.C., Lal, S., Shevell, M., Savard, G., Wong, D.F., Chouinard, G., and Gjedde, A. (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA, 91:11651-11654.
147. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose metabolism in man. Circ. Res., 44:127-137.
148. Rinne, J.O., Burn, D.J., Mathias, C.J., Quinn, N.P., Marsden, C.D., and Brooks, D.J. (1995) Positron emission tomography studies on the dopamine system and striatal opioid binding in the olivoponto-cerebellar atrophy variant of multiple system atrophy. Ann. Neurol., 37:568-573.
149. Roth, J.A. (1992) Membrane-bound catechol-O-methyltransferase: A reevaluation of its role in the O-methylation of catecholamine neurotransmitters. Rev. Physiol. Biochem. Pharmacol., 120:1-29.
150. Rousset, O.G., Ma, Y., Léger, G., Gjedde, A., and Evans, A. (1993) Corrections for partial volume effects in PET using MRI-based 3D simulations of individual human brain metabolism. In: Quantification of Brain Function. Tracer Kinetics and Image Analysis in Brain PET. K. Uemmura et al., eds. Elsevier, Amsterdam, pp. 113-120.
151. 18F]Fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J. Neurol. Neurosurg. Psychiatry, 62:622-625.
152. Sawle, G.V., Colebatch, J.G., Shah, A., Brooks, D.J., Marsden, C.D., and Frackowiak, R.S.J. (1990) Striatal function in normal aging: Implications for Parkinsons disease. Ann. Neurol., 28:799-804.
153. 18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann. Neurol., 31:166-173.
154. 18F]-6-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease. Neurology, 44:1292-1297.
155. Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy-Agid, F., and Agid, Y. (1989) Striatal dopamine deficiency in Parkinson's disease: Role of aging. Ann. Neurol., 26:551-557.
156. Shinotoh, H., Snow, B.J., Chu, N.-S., Huang, C.-C., Lu, C.-S., Lee, C., Takahashi, H., and Calne, D.B. (1997) Presynaptic and postsynaptic dopaminergic function in patients with manganese intoxication: A positron emission tomography study. Neurology, 48:1053-1056.
157. Snow, B.J., Peppard, R.F., Guttman, M., Okada, J., Martin, W.R.W., Steele, J., Eisen, A., Carr, G., Shoenberg, B., and Calne, D.B. (1990) Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amytrophic lateral sclerosis-parkinsonism-dementia complex of Guam. Arch. Neurol., 47:870-874.
158. Snow, B.J., Bhatt, M., Martin, W.R.W., Li, D., and Calne, D.B. (1991) The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J. Neurol. Neurosurg. Psychiatry, 54:12-17.
159. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol., 34:324-330.
160. Snow, B.J., Nygaard, T.G., Takahashi, H., and Calne, D.B. (1993b) Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann. Neurol., 34:733-738.
161. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem., 28:897-916.
162. Takahashi, H., Snow, B.J., Bhatt, M.H., Peppard, R., Eisen, A., and Calne, D.B. (1993a) Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet, 342:1016-1018.
163. Takahashi, H., Snow, B.J., Nygaard, T.G., and Calne, D.B. (1993b) Clinical heterogeneity of dopa-responsive dystonia: PET observations. In: Advances in Neurology, Vol. 60. H. Narabayashi et al., eds. Raven Press, New York, pp. 586-590.
164. Takikawa, S., Dhawan, V., Chaly, T., Robeson, W., Dahl, R., Zanzi, I., Mandel, F., Spetsieris, P., and Eidelberg, D. (1994) Input functions for 6-[Fluorine-18]fluorodopa quantitation in parkinsonism: Comparative studies and clinical correlations. J. Nucl. Med., 35:955-963.
165. Taniwaki, T., Sakai, T., Kobayashi, T., Kuwabara, Y., Otsuka, M., Ichiya, Y., Masuda, K., and Goto, I. (1997) Positron emission tomography (PET) in Machado-Joseph disease. J. Neurol Sci. 145:63-67.
166. 18F]fluoro-L -dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol. Scand., 81:24-30.
167. Tedroff, I., Hartvig, P., Bjurling, P., Anderson, Y., Antoni, G., and Långström, B. (1991) Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J. Neural Transm., 87:15-22.
168. 11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relation to motor response. Acta Neurol. Sand., 85:95-102.
169. Tedroff, J., Torstenson, R., Hartvig, P., Lindner, K.J., Watanabe, Y., Bjurling, P., Westerberg, G., and Långström, B. (1997) L-DOPA modulates striatal dopaminergic function in vivo: Evidence from PET investigations in non-human primates. Synapse, 25:56-61.
170. Tetrud, J.W., Langston, W., Irwin, I., and Snow, B. (1994) Parkinsonism caused by petroleum waste ingestion. Neurology, 44:1051-1054.
171. Torstenson, R., Hartvig, P., Långström, B., Westerberg, G., and Tedroff, J. (1997) Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann. Neurol., 41:334-340.
172. 11C]DOPA turnover in rat striatum with infusion of L-tyrosine. J. Neural Transm., 95:1-15.
173. 18F-dopa PET study. Neurology, 49:183-189.
174. Vingerhoets, F.J.G., Snow, B.J., Schulzer, M., Morrison, S., Ruth, T.J., Holden, J.E., Cooper, S., and Calne, D.B. (1994a) Reproducibilty of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J. Nucl. Med., 35:18-26.
175. Vingerhoets, F.J.G., Snow, B.J., Lee, C.S., Schulzer, M., Mak, E., and Calne, D.B. (1994b) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol., 36:759-764.
176. Volkow, N.D., Fowler, J.S., Gatley, S.J., Logan, J., Wang, G.-J., Ding, Y-S., and Dewey, S. (1996) PET evaluation of the dopamine system of the human brain. J. Nucl. Med., 37:1242-1256.
177. 18F]fluoro-L-dopa (FDOPA) in the brain of neonatal pigs. BrainPET 97, 3rd International Conference on Quantification of Brain Function with PET, Bethesda, MD, June 20-22.
178. Wahl, L., and Nahmias, C. (1996) Modeling of fluorine-18-6-fluoro-L-dopa in humans. J. Nucl. Med., 37:432-437.
179. 18F]6-fluoro-3-O-methyl-L -dopa in the human brain. J. Cereb. Blood Flow Metab., 14:664-670.
180. Weihmuller, F.B., Ulas, J., Nguyen, L., Cotman, C.M., and Marshall, J.M. (1992) Elevated NMDA receptors in parkinsonian striatum. NeuroReport, 3:977-980.
181. Wenning, G.K., Odin, P., Morrish, P., Rehncrona, S., Widner, H., Brundin, P., Rothwell, J.C., Brown, R., Gustavii, B., Hagell, P., Jahanshahi, M., Sawle, G., Björklund, A., Brooks, D.J., Marsden, C.D., Quinn, N.P., and Lindvall, O. (1997) Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol., 42:95-107.
182. Westerink, B.H.C., and Kikkert, R.J. (1986) Effects of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J. Neurochem., 46:1145-1152.
183. Wilson, J.M., Kalasinsky, K.S., Levey, A.I., Bergeron, C., Reiber, G., Anthony, R.M., Schmunk, G.A., Shannak, K., Haycock, J.W., and Kish, S.J. (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med., 2:699-703.
184. Wong, D.F., Harris, J.C., Naidu, S., Yokoi, F., Marenco, S., Dannals, R.F., Ravert, H.T., Yaster, M., Evans, A., Rousset, O., Bryan, R.N., Gjedde, A., Kuhar, M.J., and Breese, G.R. (1996) Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc. Natl. Acad. Sci. USA, 93:5539-5543.
185. Wood, P.L., and Altar, C.A. (1988) Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: Utility of 3-methoxytryramine measurements. Pharmacolo. Rev., 40:163-187.
186. Wszolek, Z.K., Pfeiffer, R.F., Bhatt, M.H., Schelper, R.L., Cordes, M., Snow, B.J., Rodnitzky, R.L., Wolters, E.G., Arwert, F., and Calne, D.B. (1992) Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Ann. Neurol., 32:312-320.
187. Wu, J.C., Maguire, G., Riley, G., Lee, A., Keator, D., Tang, C., Fallon, J., and Najafi, A. (1997) Increased dopamine activity associated with stuttering. NeuroReport, 8:767-770.
188. Zhu, M.Y., Juorio, A.V., Paterson, I.A., and Boulton, A.A. (1992) Regulation of the aromatic L-amino acid decarboxylase by dopamine receptors in rat brain. J. Neurochem., 58:636-641.
189. Zhu, M.Y., Juorio, A.V., Paterson, I.A., and Boulton, A.A. (1993) Regulation of striatal aromatic L-amino acid decarboxylase: Effects of blockade or activation of dopamine receptors. Eur. J. Pharmacol., 238:157-164.